BeyondSpring, Inc. - Ordinary Shares (BYSI) News
Filter BYSI News Items
BYSI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BYSI News From Around the Web
Below are the latest news stories about BeyondSpring Inc that investors may wish to consider to help them evaluate BYSI as an investment opportunity.
BeyondSpring Inc.s (BYSI) Volatility Reaches 6.26%: Dont Be ComfortableBeyondSpring Inc. (NASDAQ:BYSI) price on Friday, February 11, fall -4.81% below its previous days close as a downside momentum from buyers pushed the stocks value to $2.97. A look at the stocks price movement, the close in the last trading session was $3.12, moving within a range at $2.945 and $3.145. The beta value (5-Year BeyondSpring Inc.s (BYSI) Volatility Reaches 6.26%: Dont Be Comfortable Read More » |
BeyondSpring Inc. (NASDAQ:BYSI), 8.79% Above Its High, Could Make A Strong Comeback.In last trading session, BeyondSpring Inc. (NASDAQ:BYSI) saw 0.32 million shares changing hands with its beta currently measuring 1.09. Company’s recent per share price level of $3.07 trading at $0.08 or 2.68% at ring of the bell on the day assigns it a market valuation of $113.01M. That closing price of BYSI’s stock is at … BeyondSpring Inc. (NASDAQ:BYSI), 8.79% Above Its High, Could Make A Strong Comeback. Read More » |
BeyondSpring, Beyond SalvageNo summary available. |
BeyondSpring Cuts On-Third Of Its WorkforceBeyondSpring Inc (NASDAQ: BYSI ) plans to reduce its U.S. workforce by 35% , including reassignment of certain personnel to subsidiaries, which is expected to result in cost savings that will extend the cash runway. The reorganization follows the Full story available on Benzinga.com |
BeyondSpring Announces Organizational StreamliningResources to be Focused on Highest Value Business Activities 35% Reduction in Workforce in the U.S. Implemented to Preserve Long-Term Sustainability NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced an organizational streamlining initiative focused on prioritizing the Company’s highest value business activities, extending its |
Beyondspring (BYSI) Gets a Hold Rating from Dawson JamesDawson James analyst Jason Kolbert maintained a Hold rating on Beyondspring (BYSI – Research Report) on December 1. The company's shares closed last Tuesday at $4.74, close to its 52-week low of $3.64. According to TipRanks.com, Kolbert has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. The word on The Street in general, suggests a Hold analyst consensus rating for Beyondspring with a $11.75 average price target, implying a 136.9% upside from current levels. |
Beyondspring (BYSI) Gets a Hold Rating from H.C. WainwrightH.C. Wainwright analyst Joseph Pantginis maintained a Hold rating on Beyondspring (BYSI – Research Report) today. The company's shares closed last Thursday at $4.55, close to its 52-week low of $3.64. According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.3% and a 33.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Beyondspring with a $11.75 average price target. |
BeyondSpring Inc. (BYSI) Reports Q3 Loss, Lags Revenue EstimatesBeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 18.97% and 0.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? |
BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update- Positive Phase 3 data in 2nd/3rd line NSCLC (Dublin-3): Superior efficacy benefit in plinabulin and docetaxel combination in overall survival, 2-year and 3-year OS rate, PFS, ORR, and significant reduction of grade 4 neutropenia vs. docetaxel alone - IO combination advancement to Phase 2: plinabulin in combination with nivolumab + ipilimumab in patients in extensive-stage SCLC who progressed after at least one platinum-based chemotherapy regimen and checkpoint inhibitors (IIT study) - Wanchunb |
BeyondSpring, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmBOSTON, MA / ACCESSWIRE / December 28, 2021 / Block & Leviton is investigating BeyondSpring, Inc. (NASDAQ:BYSI) for potential securities law violations. |